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Abstract
Purpose—The categorical definition of response assessed via the Response Evaluation Criteria
in Solid Tumors has documented limitations. We sought to identify alternative metrics for tumor
response that improve prediction of overall survival.
Experimental Design—Individual patient data from three North Central Cancer Treatment
Group trials (N0026, n=117; N9741, n=1109; N9841, n=332) were used. Continuous metrics of
tumor size based on longitudinal tumor measurements were considered in addition to a
trichotomized response (TriTR: Response vs. Stable vs. Progression). Cox proportional hazards
models, adjusted for treatment arm and baseline tumor burden, were used to assess the impact of
the metrics on subsequent overall survival, using a landmark analysis approach at 12-, 16- and 24-
weeks post baseline. Model discrimination was evaluated using the concordance (c) index.
Results—The overall best response rates for the three trials were 26%, 45%, and 25%
respectively. While nearly all metrics were statistically significantly associated with overall
survival at the different landmark time points, the c-indices for the traditional response metrics
ranged from 0.59-0.65; for the continuous metrics from 0.60-0.66 and for the TriTR metrics from
0.64-0.69. The c-indices for TriTR at 12-weeks were comparable to those at 16- and 24-weeks.
Conclusions—Continuous tumor-measurement-based metrics provided no predictive
improvement over traditional response based metrics or TriTR; TriTR had better predictive ability
than best TriTR or confirmed response. If confirmed, TriTR represents a promising endpoint for
future Phase II trials.
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The high failure rate (e.g. 50-60%) of Phase III trials in oncology presents a major obstacle
to the drug discovery process (1). Understanding and addressing the potential reasons for
these high failure rates is crucial to making progress. Possible reasons for the high failure
rate in phase III trials include 1) sub-optimal choice of patient population and 2) inaccurate
predictions of effectiveness from the hypothesis generating prior Phase II trials. The focus of
the present work is on the second of these reasons, and focuses on the choice of the
endpoints used for Phase II trials in patients with measurable disease to identify agents
worthy of further evaluation. Our goal is to consider alternative Phase II endpoints to the
standardly used endpoint of tumor response, and in particular the use of endpoints based on
continuous tumor measurements.
Historically, Phase II trials have used tumor response rate as the primary endpoint, where
response is assessed via the Response Evaluation Criteria in Solid Tumors (RECIST; 2).
RECIST was implemented in an effort to standardize assessment of tumor response and has
been widely used in cancer clinical trials since 2000. Per RECIST, measurable target lesions
representative of all involved organs are identified, recorded and measured at baseline using
uni-dimensional tumor measurements. The overall patient-level objective status is then
determined based on the assessment of the target lesions, non-target lesions and new lesions.
Best response is defined as the best objective status (i.e., complete or partial response, stable
disease, or progression; each of which is based on relative change in tumor size) on
treatment. Confirmed response is defined as two consecutive assessments of complete or
partial response (CR or PR) assessed at least 4 weeks apart. Two observations are worth
noting about the RECIST criteria. First, by definition confirmed response, in contrast to best
response, requires that the response status of the patient be sustained for at least a period of
4 weeks, thus avoiding to some extent possible overestimation of the observed response rate
due to one-time measurement error. This is particularly important in non-randomized trials
where tumor response is the primary endpoint. Second, these definitions of response are
categorical and specifically, dichotomous (CR/PR or not). Modified RECIST guidelines,
RECIST 1.1, were introduced in 2009. These changes do not materially impact the subject
matter of the present paper.
The concerns over the response rate as a primary endpoint are well documented. First, there
is a demonstrated lack of concordance between response rates in single-center Phase II trials
and subsequent multicenter Phase III studies (3). More fundamentally, tumor measurements
are continuous and their categorization may result in loss of information (4). A related
concern is the use of an arbitrary cutoff to determine “response” and “no response” (5), and
timing of assessments. With the advent of targeted therapies that prolong disease
stabilization, patients may experience stable disease (SD) rather than tumor shrinkage. It has
been shown that patients with SD also achieve clinical benefit (6), and hence it is not
appropriate to ignore SD when assessing treatment efficacy.
Non-progression rate (also known as disease control rate (DCR)) has become one accepted
alternate endpoint in assessing treatment efficacy as it includes patients who achieve SD for
an extended period of time as a success, in addition to those who achieve complete or partial
response. DCR was shown to be better than response rate in predicting survival in the setting
of Non-Small Cell Lung Cancer (7). A trichotomous response has also been considered,
where response is categorized into CR/PR vs. SD vs. progression (6). Bradbury et al (8) and
Dhani et al (9) provide a recent review of the many proposed phase II trial alternate
endpoints.
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Actual tumor measurements are relatively simple to obtain and have been previously
explored by others to be used in a Phase II endpoint. Karrison et al (10) considered log
change in the sum of tumor measurements from baseline to 8 weeks as a phase II trial
endpoint. Wang et al (11) developed a model for tumor size and for survival; the primary
goal of the tumor model was to account for missing tumor measurement data. Claret et al
(12) developed a mathematical model to predict overall survival from baseline and 7-week
predicted tumor size, using a simulation study to compare observed and predicted data.
In this paper, we propose several continuous metrics based on the tumor measurements
recorded over course of treatment. We hypothesized that these continuous metrics would
more fully capture a patient’s tumor lesion experience over the course of the treatment,
compared to traditional dichotomous or trichotomous response categorization. The goal is to
identify an appropriate metric that can be assessed relatively early during treatment, which is
predictive of longer term clinical outcomes such as overall survival.
METHODS
Data
We obtained individual patient tumor measurement and survival data from three North
Central Cancer Treatment Group (NCCTG) cancer clinical trials: a Phase II first line
Pemetrexed plus Gemcitabine study in advanced non small cell lung cancer (N0026, n=157;
13), a Phase III randomized study of IFL, FOLFOX4, and IROX as first line therapy for
advanced colorectal cancer (N9741, n=1691; 14), and a Phase III randomized study of
CPT-11 vs. OXAL/5-FU/CF as second line therapy for advanced colorectal cancer (N9841,
n=491; 15). N0026 had three treatment arms in which none was found superior (overall
response rate RR = 19%). N9741 randomized patients to three treatment arms IFL (Arm A),
FOLFOX (Arm F) and IROX (Arm G). Arm F was found to be the most effective treatment,
arm A was the previous standard of care, and arm G was found to have some efficacy but
high toxicity. Overall RR for N9741 was 38%. N9841 had two treatment arms between
which there was no difference found in overall survival (overall RR = 22%).
All patients with measurable disease who had a baseline measurement as well as at least one
post-baseline measurement were included in our analysis. Patients who progressed or went
off study for any reason prior to their first post-baseline measurement were excluded. The
analysis dataset therefore included 117, 1109, and 332 patients from N0026, N9741, and
N9841 respectively; with associated response rates of 26%, 45%, and 25% respectively.
Baseline characteristics for the patients included in the analyses are summarized in Table 1.
Both N9841 and N0026 utilized the RECIST criteria measurement for collection and
assessment. N9741 opened prior to RECIST and instead collected and assessed tumor
measurements according to WHO criteria. Applying the RECIST criteria to N9741 data, we
used the maximum of the two measurements recorded for each lesion. The number of
lesions measured at each assessment varied over time within patients, thus only lesion
measurements that were available across all assessments for the patient were utilized. Each
study was designed to assess the lesions at 4-6 week intervals and assessed up to 10 lesion
measurements.
Metrics
The continuous metrics we consider are based on the tumor measurements recorded over
course of treatment. As such, these metrics are different than previously considered work on
continuous tumor measurements (e.g., of tumor size at k-weeks for some fixed k) in that
these capture an overall tumor burden over the course of study. Table 1 summarizes the
metrics. The total sum of measurements (TSM) was calculated simply as the sum of
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measurements at each assessment starting from baseline. To account for total time on study,
we considered the average sum of measurements (ASM), which is calculated by dividing the
TSM by the total number of assessments. As another metric, we considered the relative
change from baseline (RCB), defined as follows: for each assessment, divide the sum of
measurements at that assessment by the sum of the baseline measurements and subtract 1
from this ratio, and then sum this quantity over all assessments. With this definition,
negative values of the RCB indicate a decrease in tumor measurements. We also considered
the average relative change from baseline (ACB), which is the RCB divided by the number
of assessments. In addition to these continuous metrics, we also considered trichotomized
response, defined as CR/PR vs. Stable vs. Progression, using the RECIST criteria. In
particular, we considered trichotomized response (TriTR) status at a pre-defined timepoint
and best trichotomized response (Best TriTR), as well as the traditional confirmed response.
Statistical Analysis
Both the total sum of measurements (TSM) and the average sum of measurements (ASM)
were log-transformed to normalize the distribution in order to satisfy model assumptions.
Distributions of other continuous metrics appeared approximately symmetric and unimodal,
and therefore were not transformed. A Cox proportional hazards model adjusting for the
metric, treatment arm, and sum of baseline measurements (i.e., baseline tumor burden) was
fit, where the metrics were calculated from tumor measurements available at randomization
(baseline) until (1) 12-weeks post-randomization (12-week landmark analysis); (2) 16-weeks
post-randomization (16-week landmark analysis); and (3) 24-weeks post-randomization (24-
week landmark analysis). In each analysis, we considered the continuous metrics, confirmed
response, trichotomized best response, and trichotomized response status at the pre-defined
timepoints. For this last metric, the objective status at the assessment closest to that time
point, i.e. within 3 weeks from the expected assessment time, was utilized. When utilizing a
landmark analysis approach, TSM and ASM are theoretically equivalent since they only
differ by a constant factor, that is, TSM divided by the number of assessments yields the
ASM. However not all patients have the same number of assessments in a given time period
so that ASM and TSM do not necessarily differ by a constant factor across all patients. We
have therefore included both metrics for consideration. A similar comment applies to RCB
and ARCB.
To understand the associations between each metric and survival, we considered hazard
ratios for each metric. As a measure of model fit and a means to compare non-nested
models, we considered the Akaike Information Criteria (AIC).
Discrimination and calibration were considered to better understand predictive utility of our
response metrics, our primary goal. To determine how well a model (and by extension, a
metric) discriminates among patients with different outcomes we utilized the concordance
index (or c-index; 16-17). The c-index in the context of survival considers all pairs of
individuals. If one can determine which individual in the pair first died, then this pair is
evaluable. If the patient with a higher estimated hazard ratio dies prior to the one with a
lower estimated hazard ratio then the pair is deemed concordant, otherwise they are
considered discordant. The index is the fraction of all evaluable pairs that are concordant. It
ranges from 0.5 to 1.0 where 0.5 indicates no association and 1 indicates perfect association.
We assessed calibration by comparing expected and observed survival probabilities at 1-year
as follows: patients were grouped into deciles of their predicted probabilities from a Cox
model. Within each decile, we calculated the average predicted probability (“expected”) and
the Kaplan-Meier estimate (“observed”), and compared these in plots and via an informal
measure calculated as the sum of the squared difference between expected and observed
probabilities. In comparing metrics, our focus was on discrimination.
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Table 3 provides results from the 12-week landmark analysis, adjusting for metric, treatment
arm and sum of baseline measurements. Figure 1 presents the c-indices for all 7 metrics
(represented by different symbols) for each study. In this section, unless otherwise noted, we
present results from the 12-week landmark analysis. Results for the 16- and 24-week
landmark analyses were similar and are included as supplemental tables.
All of the categorical and continuous response metrics were found to be statistically
significantly associated with overall survival (hazard ratios, p<0.05; Table 3). The AIC
values ranged from 799 (for the model with ASM) to 815 (for Confirmed Response) in
N0026; from 11872 (for TriTR) to 12699 (for Confirmed Response) in N9741; and from
2987 (for ARCB) to 3058 (for RCB) in N9841.
Based on the plots and measure of observed versus expected 1-year survival probabilities,
calibration across models was reasonable and comparable (Figure 2; Supplemental Figures
1-2). Plots for 2- and 3-year survival probabilities (not shown) revealed similar findings. The
c-indices for confirmed response ranged from 0.59-0.65; for the continuous metrics, from
0.60-0.66; and for TriTR metrics, from 0.64-0.69 (Table 3). Three observations regarding
the c-indices hold across all three studies. First, while continuous metrics were all
statistically significantly associated with overall survival (via hazard ratios; Table 3), they
provided minimal (if any) improvement in prediction for overall survival compared to the
various categorical response metrics based on the c-index. In Figure 1, the c-indices for
categorical response metrics (open circles, open point-down triangles, and solid circles;
range: 0.59-0.69 from Table 3) are as high as or higher than those for continuous metrics
(other symbols; range: 0.60-0.66 from Table 3). This suggests that in general the categorical
response metrics may be better predictors of overall survival than the continuous metrics.
Second, the c-indices for trichotomized response status at 12-weeks (solid circles; range:
0.64-0.69 from Table 3) are at least as high as or higher than those for best trichotomized
response (open circles; range: 0.64-0.67 from Table 3) and confirmed response (open point-
down triangles; range: 0.59-0.65 from Table 3) within the same time frame. Third, the c-
indices for trichotomized response at 12-weeks (solid circles; range: 0.64-0.69) are
comparable to those for trichotomized response at 16- and 24-weeks (range: 0.65-0.70 and
0.65-0.66 respectively from Supplemental Tables). As reference, we also calculated the c-
indices for models that only included treatment and baseline sum of measurements based on
measurement data available at 12-weeks. These were 0.59, 0.61, and 0.64 for N0026,
N9741, and N9841 respectively.
All of these analyses were also repeated within each arm for N9741, the large randomized
trial, and the results were similar (data not shown). Of note is that the c-indices for response
at 12-weeks were consistently as high as or higher than those for other metrics. Figure 3
shows Kaplan-Meier survival curves by trichotomized response status at 12-weeks and by
ACB (dichotomized at the median) for each study.
DISCUSSION
Contrary to our hypothesis, we found that the continuous metrics we assessed provide no
predictive advantage over the categorical response metrics. However, we do recommend
further study of the trichotomized response at early time points (e.g. 12-, 16-, and 24-weeks)
with particular attention to 12-week status. This metric has at least two advantages. First, it
addresses the concern over ignoring stable disease by including SD as a separate category;
second it can be assessed earlier since it does not require confirmation and does not require
data from the entire study period.
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It is interesting to note that N0026 and N9841 had relatively low response rates (25-26%),
yet the trichotomized response still performed as well as in N9741 which had a higher
response rate (45%). Likely the trichotomized response appropriately recognizes the survival
benefit associated with stable disease by placing such patients into their own category rather
than combined in the same category as progression. A natural extension to the trichotomized
response would be a 5-level metric (CR vs. PR vs. Stable vs. Increasing vs. Prog). However,
this also has some inherent limitations, specifically, 1) the need to specify a cut-point to
distinguish between Increasing and Progression, where the choice for this is not obvious,
and 2) the complete response (CR) rate is often small in oncology studies, for example, in
our data, the CR rates for N0026, N9741, and N9841 were 0%, 4.2%, and 3.3% respectively.
The inability for the continuous metrics we assessed to improve survival prediction may be
due to several factors. First, when considered over an entire study population, tumor growth
may be sufficiently ‘regular’ that measurements at a fixed time point post-baseline
adequately characterize tumor activity. Second, the imaging frequency could be too
infrequent to capture the tumor size changes. Alternatively, unidimensional tumor size may
not be the most accurate measure of disease aggressiveness; functional imaging, volumetric
assessment, or other advanced imaging methods may offer improvements. Finally, it may be
too much to expect any early tumor measurement related endpoints to predict overall
survival in settings where second and later line therapies are used (18). An important
assumption for the validity of endpoints based on our continuous metrics is that patient
tumors are measured at regular intervals which do not differ by arm. This is to eliminate the
possible bias that could arise in the following situation: two patients have similar tumor
growth trajectories, but one has a tumor measurement at j weeks and the other has a tumor
measurement as j+i weeks (for i>0) by which time the tumor is a different size than at week
j. As a result, these patients may have different tumor response profiles based on our
continuous metrics
An additional limitation to the current data is the inability to effectively assess the impact of
the missing measurement data due to clinical progression, new lesions and missing
assessments. Moreover, the number of lesions measured at each assessment was variable,
and the current analysis used only the lesion measurements that were available across all
assessments for the patient. Since not all lesion measurements at each assessment were used,
the measurement data from each cycle used to compute the metrics could be biased. Future
work should consider further exploration of trichotomized response as well as alternative
continuous metrics since simple scalar summaries such as those we considered may not
likely capture “the” key features of the tumor growth curve. For example, it is possible to
have one patient for whom the tumor decreases over time and another patient for whom
tumor increases over time, but for these two patients to have identical sums of
measurements. Further, tumor growth curves often exhibit non-linearity, e.g. initial tumor
shrinkage followed by progression. In order to capture key features of the tumor growth
curve and thereby to improve prediction, a metric will likely need to be composite, for
example, a linear combination of multiple scalar summaries such as those considered in this
paper. Longitudinal modeling, e.g. mixed models, is another option others have previously
considered (e.g. 12).
In conclusion, our data suggest that categorical response metrics predict survival as well as
or better than the continuous tumor-measurement-based metrics considered in this work.
Furthermore, trichotomized response at early timepoints, possibly as early as 12-weeks, are
worthy of further study as an alternative endpoint in Phase II trials.
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STATEMENT OF TRANSLATIONAL RELEVANCE
The high failure rate (e.g. 50-60%) of Phase III trials in oncology, attributable in part to
less than optimal predictions of effectiveness from hypothesis generating Phase II trials,
presents a major obstacle to the drug discovery process. Historically, Phase II trials have
used (categorical) tumor response rate as the primary endpoint, an approach that has
documented concerns. In this paper, we explore longitudinal tumor measurement-based
continuous metrics and alternative categorical response metrics. Our results suggest that
an unconfirmed trichotomized objective status assessed as early as 12-weeks post
treatment initiation predicts for subsequent survival as well as or better than traditional
response based or our continuous metrics. This trichotomized objective status metric, if
validated, may positively impact the drug development process by: a) accurately
reflecting the intended goals of current therapies, b) shortening assessment time, and c)
improving prediction of subsequent survival.
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C-Indices from survival models adjusted for metric, treatment arm and sum of baseline
measurements
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Plots of observed versus expected 1-year survival probabilities for N9741 based on models
for each metric and a model with no metric, adjusting for treatment arm and sum of baseline
tumor measurements
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Kaplan-Meier Survival Curves by Dichotomized Average Change since Baseline (ACB)
(left column) and Trichotomized Response (TriTR) (right column) at 12-weeks, for each
study (row)
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Trichotomized Best Response (Best TriTR) Best objective status (CR/PR vs. Stable vs. Progression)
Confirmed Response Two consecutive assessments of complete or partial response assessed at least 4 weeks
apart (CR/PR vs. no CR/PR)
Trichotomized Response Status (TriTR) at a
pre-defined timepoint
Objective status at the assessment closest to the pre-defined timepoint (CR/PR vs. Stable
vs. Progression)
Total Sum of Measurements (TSM) Sum of measurements at each assessment
Average Sum of Measurements (ASM) Sum of measurements divided by the number of assessments
Relative change from baseline (RCB) Sum of the relative changes since baseline, calculated as follows: divide the sum of
measurements at each assessment by the sum of the baseline measurements and subtract 1;
then sum this quantity over all assessments
Average relative change from baseline (ARCB) RCB divided by the number of assessments
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Table 2
Baseline characteristics of patients included in analysis.
Characteristics N0026 (N=117) N9741 (N=1109) N9841 (N=332)
Age: Median (Range) 65 (39, 81) 61 (19, 85) 63 (28, 86)
PS: 0-11 117 (100%) 1062 (96%) 321 (97%)
  2 0 (0%) 47 (4%) 11 (3%)
Male 70 (60%) 692 (62%) 195 (59%)
Stage: IIIB 16 (14%) 0 (0%) 0 (0%)
   IV2 101 (86%) 1109 (100%) 332 (100%)
Overall Survival (Years): Median (95% CI) 1.1 (1.0, 1.4) 1.6 (1.5, 1.7) 1.0 (1.0, 1.2)
% Alive3: 2 Years 13 (11%) 198 (18%) 42 (13%)
    3 Years 8 (7%) 88 (8%) 11 (3%)
    4 Years 9 (8%) 52 (5%) 4 (1%)
    5 Years 5 (4%) 62 (6%) 4 (1%)
Overall Confirmed Response Rate (RR) 30 (26%) 498 (45%) 83 (25%)
1
Per eligibility criteria for N0026.
2
Per eligibility criteria for N9741 and N9841.
3
Percent alive at year and up to following year.
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